Dr. Manfred Rieger
Site Head and Managing Director of Takeda Research & Development in Austria
Takeda
Vienna, Austria
About me
Dr. Manfred Rieger is the site head and managing director of Takeda R&D (Research & Development) in Austria. He has more than 20 years of experience in the pharmaceutical sector, where he was responsible for both pharmaceutical development and the development of manufacturing processes. For several years he has managed the transition of pharmaceutical products from the clinical development phase to commercial manufacturing. Dr. Rieger has extensive knowledge of R&D processes and has gained a lot of experience as head of clinical trial managers (internal) and clinical research organizations (external). During his career, he has also been responsible for the management of international external partnerships with government agencies, universities and start-ups. In addition, Mr. Rieger is responsible for the new Takeda research & development building - the Lab of the Future - in Seestadt Aspern, which will open in 2026. Dr. Rieger holds a PhD in Biotechnology from the University of Natural Resources and Life Sciences in Vienna and has written numerous scientific articles on hematology and immune-mediated diseases.
My organisation
About Takeda globally: Takeda is a globally leading, values-oriented, research-driven biopharmaceutical company headquartered in Japan. Takeda aims to develop and produce life-improving and life-saving medicines for the treatment of rare and complex diseases. The focus is on providing care for patients who have few or no treatment options available. At Takeda, the commitment to patients, employees, and the environment is always at the forefront. https://www.takeda.com
About Takeda in Austria: In Austria, every step of the process for innovative medicines takes place at Takeda: from research & development, plasma application and production, to patient care. Around 4,500 employees help to ensure that medicines from Austria reach over 100 countries worldwide and that patients in Austria have access to Takeda's innovative medicines. The Austrian product portfolio helps patients in the fields of oncology, rare metabolic diseases, gastroenterology and immunology, among others. Takeda has also been recognized as a certified Top Employer for its outstanding employee experience and commitment to inclusion and is a pioneer in sustainable and responsible drug production. https://www.takeda.at
Speaker sessions (1)
Thursday, 28 November 2024
10:25 - 10:55